May 10, 2022 - Portal Instruments has been featured in Fierce Pharma. "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
May 10, 2022 -Yesterday, Fierce Pharma published an article showcasing Gerresheimer's investment into Portal Instruments. The article titled, "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
Read the full article here:
March 2021 - With the COVID-19 vaccine becoming more readily available, there is the outstanding question of how many people will get vaccinated and will it be enough to help society as a whole achieve herd immunity.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
November 2024, Cambridge, MA – Seasoned drug delivery executive, Steven Kaufman, to join Portal Instruments as their Chief Commercial Officer. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
Please fill out the details below and we will get back to you shortly.